VALEANT PHARMA REVEALS SEC'S INFORMAL INQUIRY INTO ITS STOCK OPTION GRANTS, RELEASE OF DATA ON VIRAMIDINE

Costa Mesa, California-based Valeant Pharmaceutical International on Monday morning announced that the Securities and Exchange Commission or SEC is conducting an informal inquiry on the events and circumstances surrounding trading of its common stock and the public release of data from its first pivotal Phase 3 trial for Viramidine, a prodrug of ribavirin for the treatment of chronic hepatitis C.
Trading Markets